World's First HPV Genotyping & Normalized Quantification Assay: Clinical Breakthroughs and Evidence-Based Impact

Join BioPerfectus' webinar on innovative HPV screening enhancing cervical cancer prevention. Learn more on WebinarCafe

Healthcare Webinar Benefits

As the world’s first developer of the HPV Genotyping & Normalized Quantification Assay, BioPerfectus cordially invites you to join our exclusive webinar and witness this transformative breakthrough in cervical cancer prevention.

June 19, 2025, 11:30 AM (UTC)

Register Now

Next-Gen Cervical Screening: Integrating Genotyping with Viral Load

Despite decades of progress, cervical cancer remains a leading cause of cancer-related deaths among women globally. Traditional screening methods struggle to balance underscreening gaps and overtreatment risks—a dilemma now addressed by genotype-specific viral load quantification.

Cervical cancer screening is evolving from the qualitative "positive/negative" paradigm to a precision-driven era of genotyping paired with standardized viral load quantification—a dual-strategy approach that redefines clinical decision-making.

Global Guidelines Insight

Consensus on HPV viral load standardization from leading guidelines.

Cutting-Edge Technology

21 HPV genotype detection + single-copy gene-based normalized quantification.

Evidence-Driven Validation

Proof from clinical studies, aligned with international standards.

Critical Clinical Value

Role of HPV viral load in cervical lesion risk stratification, treatment efficacy tracking, and prognosis monitoring.

Agenda Highlights:

11:30 – 11:40 UTC: Welcome & Agenda Overview

11:40 – 12:25 UTC: Expert Talk: Global Trends in HPV Diagnostics

12:25 – 12:35 UTC: Solution Showcase + Genotyping & Quantification Demo

12:35 – 12:50 UTC: Live Q&A Session – Ask the Experts!

About the Speaker: Prof. Pengming Sun, MD, PhD, a globally recognized leader in HPV detection and cervical cancer prevention.